Enliven Therapeutics (ELVN)

• Market cap: $1B
• 1 day: -10.18%
• 5 days: -23.08%
• 1 month: -16.95%
• 3 months: -15.53%
• 6 months: -14.24%
• Year to date: -29.46%
• 1 year: -26.7%
• 5 years: -82.54%
• 10 years: -71.9%
• Sector: Healthcare
• Industry: Biotechnology

About: Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.

Employees: 65